Raymond A Clark

US Patent:

7919475, Apr 5, 2011

Filed:

Aug 25, 2005

Appl. No.:

11/574232

Inventors:

Wolfgang Dillmann - Solana Beach CA, US
Raymond Clark - San Marcos CA, US

Assignee:

The Regents of The University of California - Oakland CA

International Classification:

A61K 48/00
A01N 63/00
C07H 21/02
C07H 21/04

US Classification:

514 44R, 424 9321, 435325, 536 231, 536 232

Abstract:

The present invention relates to treating or ameliorating heart disease associated with poor myocardial performance, e. g. , diabetic cardiomyopathy and associated disorders, particularly to treating, preventing or ameliorating such disorders through inhibition of O-GlcNAcylation and/or increased activity of O-GlnNAcase. The invention provides vectors for gene transfer of O-GlnNAcase. In one aspect, the invention provides cells, vectors, formulations comprising them and methods of using them, for the gene transfer of the human O-GlnNAcase gene, e. g. , to treat conditions and diseases associated with impaired cardiac contractility, such as that, found associated with diabetic cardiomyopathy. In another aspect, the invention provides non-human transgenic animals and host cells comprising genetically engineered cells having increased activity of O-GlnNAcase.